Glass House Brands (GLAS) Non-Current Assets (2020 - 2026)
Glass House Brands' (GLAS) quarterly Non-Current Assets came in at $251.0 million in Q1 2026, up 3.27% year-on-year from $243.0 million in Q1 2025, and up 3370.7% on a QoQ basis from $7.2 million in Q4 2025.
Glass House Brands (GLAS) Non-Current Assets (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Non-Current Assets data on file, last reported at $251.0 million in Q1 2026.
- On a quarterly basis, Non-Current Assets rose 3.27% year-over-year to $251.0 million in Q1 2026; TTM through Mar 2026 was $987.6 million, a 0.74% decrease from a year earlier, with the FY2025 full-year figure at $7.2 million, up 66.91% from the prior year.
- Non-Current Assets for Q1 2026 stood at $251.0 million, up from $7.2 million in the prior quarter.
- Over the last five years, Non-Current Assets for GLAS reached as high as $304.3 million in Q3 2022 and fell as low as $2.4 million in Q4 2022.
- Historically, Non-Current Assets has averaged $200.1 million across 5 years, with a median of $248.1 million in 2025.
- Across the five-year window, Non-Current Assets jumped 430.62% in 2022 and retreated 12.96% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $2.4 million in 2022, then jumped by 78.8% to $4.2 million in 2023, then advanced by 2.78% to $4.3 million in 2024, then jumped by 66.91% to $7.2 million in 2025, then surged by 3370.7% to $251.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $251.0 million in Q1 2026, $7.2 million in Q4 2025, and $245.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 3.84 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 18.82 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 251.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.00 Mn |
| Dec 31, 2025 | 7.23 Mn |
| Sep 30, 2025 | 245.48 Mn |
| Jun 30, 2025 | 248.06 Mn |
| Mar 31, 2025 | 243.04 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 245.40 Mn |
| Jun 30, 2024 | 253.38 Mn |
| Mar 31, 2024 | 253.17 Mn |
| Dec 31, 2023 | 4.22 Mn |
| Sep 30, 2023 | 281.93 Mn |
| Jun 30, 2023 | 277.30 Mn |
| Mar 31, 2023 | 286.84 Mn |
| Dec 31, 2022 | 2.36 Mn |
| Sep 30, 2022 | 304.29 Mn |
| Jun 30, 2022 | 262.50 Mn |
| Mar 31, 2022 | 230.59 Mn |
| Dec 31, 2021 | -62.91 Mn |
| Sep 30, 2021 | 208.06 Mn |
| Jun 30, 2021 | 49.47 Mn |